OncoMatch/Clinical Trials/NCT05773040
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
Is NCT05773040 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies JV-213 for lymphomas.
Treatment: JV-213 — To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-CD20 antibody — LBCL, FL, marginal zone lymphoma, MCL, Burkitt lymphoma
anti-CD20 antibody
Must have received: anthracycline — LBCL, Burkitt lymphoma
anthracycline therapy
Must have received: alkylating agent — FL, marginal zone lymphoma, MCL
alkylating agent
Must have received: lenalidomide (lenalidomide) — FL, marginal zone lymphoma
lenalidomide therapy
Must have received: BTK inhibitor — marginal zone lymphoma, MCL
BTK inhibitor therapy
Cannot have received: CAR-T cell therapy using non-FMC63 antibody
Any CAR cell therapy using non-FMC63 antibody
Cannot have received: autologous stem cell transplant
Exception: within 6 weeks
Autologous stem cell transplantation within 6 weeks
Cannot have received: allogeneic stem cell transplant
Exception: within 3 months or active graft versus host disease
Allogeneic stem cell transplantation within 3 months or active graft versus host disease
Lab requirements
Blood counts
Absolute neutrophil count of ≥1.0×10^9/L; Absolute lymphocyte count of ≥0.1×10^9/L; Platelet count of ≥75×10^9/L
Kidney function
Creatinine clearance (as estimated by Cockcroft Gault) ≥45 mL/min
Liver function
Serum alanine transaminase (ALT) / aspartate transaminase (AST) ≤5 times the upper limit of normal (ULN); Total bilirubin ≤2 mg/dL, except in patients with Gilbert's syndrome.
Cardiac function
Cardiac ejection fraction ≥45% with no evidence of clinically significant pericardial effusion
Absolute neutrophil count of ≥1.0×10^9/L; Absolute lymphocyte count of ≥0.1×10^9/L; Platelet count of ≥75×10^9/L; Creatinine clearance (as estimated by Cockcroft Gault) ≥45 mL/min; Serum alanine transaminase (ALT) / aspartate transaminase (AST) ≤5 times the upper limit of normal (ULN); Total bilirubin ≤2 mg/dL, except in patients with Gilbert's syndrome; Cardiac ejection fraction ≥45% with no evidence of clinically significant pericardial effusion
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05773040 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy using non-FMC63 antibody, autologous stem cell transplant, allogeneic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify